Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Amir R Afshari"'
Publikováno v:
BioFactors.
The Current State of Potential Therapeutic Modalities for Glioblastoma Multiforme: A Clinical Review
Autor:
Negar Shafaei-Bajestani, Amirhossein Sahebkar, Elmira Mohtashami, Amir R Afshari, Seyed Hadi Mousavi, Mohammad Jalili-Nik, Hamid Mollazadeh
Publikováno v:
Current Drug Metabolism. 21:564-578
Glioblastoma multiforme (GBM), as the most lethal brain tumor, continues to be incurable. Considering the high mortality rate of GBM, it is crucial to develop new treatment approaches. Conventional therapies, including maximal surgical resection, rad
Autor:
Gordon A. Ferns, Amir R Afshari, Fereshteh Asgharzadeh, Farzad Rahmani, Atena Soleimani, Jalal Naghinezhad, Mohammad-Hassan Arjmand, Amir Avan, Maryam Moradi Binabaj, Majid Khazaei, Saeedeh Mehraban, Sayyed Hadi Sayyed‐Hosseinian, Mikhail Ryzhikov, Maryam Fakhraei, Mohammad Reza Parizadeh, Seyed Mahdi Hassanian
Publikováno v:
Journal of Cellular Physiology. 235:1349-1357
Here, we have investigated the therapeutic potency of EW-7197, a transforming growth factor-β type I receptor kinase inhibitor, against postsurgical adhesion band formation. Our results showed that this pharmacological inhibitor prevented the freque
Autor:
Hamid Mollazadeh, Mohammad Jalili-Nik, Hamed Sabri, Amirhossein Sahebkar, Amir R Afshari, Bahram Bibak
Publikováno v:
BioFactors (Oxford, England)REFERENCES. 47(5)
The most widespread and challenging aggressive malignant tumor in the brain is glioblastoma multiforme (GBM). GBM is characterized, in particular, by significant intratumor cell variability, high growth rates, and widespread invasiveness within the s
Autor:
Amirhossein Sahebkar, Hamid Mollazadeh, Amir R Afshari, Arash Soltani, Hossein Javid, Elmira Mohtashami, Erfan Tavana, Seyed Mohamad Sadegh Modaresi, Azar Hosseini, Hamed Sabri
Publikováno v:
BioFactors (Oxford, England)REFERENCES. 46(3)
Quercetin, a plant-derived flavonoid, is known for its antitumor and antiproliferative activities. Glioblastoma multiforme (GBM), as a highly aggressive cerebrum tumor, has a poor prognosis that is approximately 12 months despite standard therapy. Th